Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308133 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16349058 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL14401914 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13689098 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL8353738 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL14451045 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13305538 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL4304713 | 0.88 | NR1H2 (0.34) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL4311042 | 0.88 | NR1H2 (0.34) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16843376 | 0.87 | NR1H2 (0.35) | HSD17B10NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20160326216-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-11-10 | — | — | US | disclosed |
| US-9422333-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150175657-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-06-25 | — | — | US | disclosed |
| US-8980935-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8524760-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8188137-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885NR1H2 1970/4885SMN1; SMN2 4140/4885 |
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | HSD17B10 3574/4885NR1H2 1773/4885SMN1; SMN2 1912/4885 |
| US-20160326216-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885NR1H2 1970/4885SMN1; SMN2 4140/4885 |
| US-20150175657-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885NR1H2 1970/4885SMN1; SMN2 4140/4885 |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | HSD17B10 1134/4885NR1H2 2482/4885SMN1; SMN2 3511/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | HSD17B10 2728/4885NR1H2 3845/4885SMN1; SMN2 4842/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885NR1H2 1970/4885SMN1; SMN2 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.